Biotech advancements show promise in treating aging and age-related diseases

Recent developments in biotechnology highlight new approaches to aging and age-related diseases. Insilico Medicine has developed rentosertib, an AI-designed drug originally intended to treat idiopathic pulmonary fibrosis. Research published in Nature Biotechnology indicates that patients treated with the molecule showed signs of biological rejuvenation, with six different proteomic aging clocks measuring a reduction in biological age by approximately three to four years.

In a separate advancement, San Diego-based biotech Epirium Bio is advancing the MF-300 molecule into Phase 2 human testing. The drug is a small-molecule inhibitor targeting 15-PGDH, an enzyme categorized by Stanford scientists as a “gerozyme.” These proteins increase in activity with age and disrupt the body’s natural repair mechanisms. By inhibiting 15-PGDH, the drug aims to increase levels of prostaglandin E2 to promote tissue repair. While initial trials focused on sarcopenia (age-related muscle loss), the research suggests potential applications for treating joint, bone, and brain-related age degeneration.